Adult Growth Hormone Deficiency (AGHD) Market Share Analysis, Growth Opportunities, and Challenges, Treatment Algorithm, Emerging Pipeline Therapies, Epidemiology Insights| Key Companies
DelveInsight has launched a new report on “Adult Growth Hormone Deficiency (AGHD) Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “Adult Growth Hormone Deficiency (AGHD) Market Insights, Epidemiology, and Market Forecast-2032″ report offer an in-depth understanding of the Adult Growth Hormone Deficiency (AGHD), historical and forecasted epidemiology as well as the Adult Growth Hormone Deficiency (AGHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Adult Growth Hormone Deficiency (AGHD) Market Report:
- According to the research, about 15%-20% of the cases represent the transition of childhood GH deficiency into adulthood
- As per Jana Bujanova et al., the estimated prevalence of AGHD in the UK is approximately 1 in 10 000 (a total of approximately 6380 patients)
- As per the studies, the prevalence of Adult Growth Hormone Deficiency is more common among males than females
- According to Growth hormone Foundation estimates, more than 50,000 adults in the United States are growth hormone deficient, and 6,000 new cases are reported each year
Request a sample for the Report: https://www.delveinsight.com/sample-request/adult-growth-hormone-deficiency-aghd-market
Key benefits of the report:
- Adult Growth Hormone Deficiency (AGHD) market report covers a descriptive overview and comprehensive insight of the Adult Growth Hormone Deficiency (AGHD) Epidemiology and Adult Growth Hormone Deficiency (AGHD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Adult Growth Hormone Deficiency (AGHD) market report provides insights on the current and emerging therapies.
- Adult Growth Hormone Deficiency (AGHD) market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Adult Growth Hormone Deficiency (AGHD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Adult Growth Hormone Deficiency (AGHD) market.
Got queries? Click here to know more about the Adult Growth Hormone Deficiency (AGHD) Market Landscape
Adult Growth Hormone Deficiency (AGHD) Overview:
Adult-Onset Growth Hormone Deficiency (AGHD) is a medical condition that occurs when the body does not produce enough growth hormone. It stimulates the release of another hormone called insulin-like growth factor 1, which is produced mainly by the liver. Together, these hormones produce growth in childhood and, in adult life, have widespread metabolic effects throughout the body.
Most cases of adult-onset growth hormone deficiency result from damage to the pituitary gland caused by the development of a pituitary tumor or by treatment for this using surgery and/or radiotherapy. Pituitary damage can also result from radiotherapy to the brain for other tumors close to the pituitary gland or for leukemia, from a severe head injury, autoimmune disease, or from interference with the blood supply to the pituitary gland (for example in Sheehan’s syndrome or pituitary apoplexy).
Adult Growth Hormone Deficiency (AGHD) Symptoms:
The symptoms of Adult-Onset Growth Hormone Deficiency include –
- Changes in memory, processing, and attention
- Lack of well-being
- Depression
- Anxiety
- Social Isolation
- Body Fatigue
- Lack of strength
Adult Growth Hormone Deficiency (AGHD) Market
The dynamics of the Adult Growth Hormone Deficiency (AGHD) market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Somavaratan, Genotropin, and others during the forecasted period 2019-2032.
Learn more by requesting for sample @Adult Growth Hormone Deficiency (AGHD) Market Landscape
Adult Growth Hormone Deficiency (AGHD) Pipeline Therapies:
- Genotropin
- Somavaratan
- Macimorelin
- Growth hormone – LB03002
Adult Growth Hormone Deficiency (AGHD) Pipeline Key Companies:
- Hanmi Pharmaceutical
- GeneScience Pharmaceuticals
- BioPartners GmbH
- AEterna Zentaris
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Adult Growth Hormone Deficiency (AGHD) Patient Share (%) Overview at a Glance
5. Adult Growth Hormone Deficiency (AGHD) Market Overview at a Glance
6. Adult Growth Hormone Deficiency (AGHD) Disease Background and Overview
7. Adult Growth Hormone Deficiency (AGHD) Epidemiology and Patient Population
8. Country-Specific Patient Population of Adult Growth Hormone Deficiency (AGHD)
9. Adult Growth Hormone Deficiency (AGHD) Current Treatment and Medical Practices
10. Unmet Needs
11. Adult Growth Hormone Deficiency (AGHD) Emerging Therapies
12. Adult Growth Hormone Deficiency (AGHD) Market Outlook
13. Country-Wise Adult Growth Hormone Deficiency (AGHD) Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Adult Growth Hormone Deficiency (AGHD) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about our Competitive Services, Click here: Pharma Competitive Intelligence
https://www.delveinsight.com/consulting/competitive-intelligence-services
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com